Fujian Haixi Pharmaceuticals Co., Ltd. (HKG:2637)

Market Cap	14.90B
Revenue (ttm)	648.05M +24.8%
Net Income	197.00M
EPS	2.83
Shares Out	78.71M
PE Ratio	66.79
Forward PE	68.48
Dividend	n/a
Ex-Dividend Date	n/a

Volume	60,050
Open	180.00
Previous Close	189.30
Day's Range	178.90 - 188.60
52-Week Range	97.50 - 302.40
Beta	n/a
Analysts	Buy
Price Target	346.75 (+89.69%)
Earnings Date	Mar 30, 2026

About HKG:2637

Fujian Haixi Pharmaceuticals Co., Ltd. engages in research and development, production, and sale of pharmaceutical products in China. The company offers drugs for oncology, ophthalmology, respiratory, digestion, cardiovascular, endocrine, and nervous systems, and inflammation. It also provides pharmaceuticals technical services. In addition, the company offers generic alternatives, such as Anbili, a generic of mosapride citrate tablets; Haihuitong 5mg/10mg and 5mg/20mg, a generic of amlodipine besilate and atorvastatin calcium tablets; Ruiantuo...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2012
• Employees: 200
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2637

Financial Performance

In 2025, HKG:2637's revenue was 582.36 million, an increase of 24.79% compared to the previous year's 466.68 million. Earnings were 177.03 million, an increase of 30.09%.

Financial numbers in CNY

Analyst Summary

According to one analyst, the rating for 2637 stock is "Buy" and the 12-month stock price target is $346.75.

Price Target

$346.75

(89.69% upside)

Analyst Consensus: Buy